TRACER (S1415CD) NEWSLETTER

March 2017

STUDY UPDATES

A TrACER abstract about the TrACER application data was accepted for poster presentation at AACR in Washington, D.C. in April 2017.

UPCOMING EVENTS

Mark your calendars!

On **Thursday, April 27th from 10 - 12** we will host a TrACER update meeting at SWOG. The meeting will provide an opportunity for participating sites to meet and share best practices for setting up standing orders, patient recruitment and other pertinent topics. Light refreshments will be provided. We hope to see you all there!

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind, and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR, and funded in part by PCORI.

CONGRATULATIONS AND THANK YOU

Congratulations to the following sites who have completed their order change process as of 3/7/17:

- ★ Billings Clinic Cancer Center in Billings, MT
- ★ Bozeman Deaconness Cancer Center in Bozeman, MT
- ★ Contra Costa Regional Medical Center in Martinez, CA
- ★ Essentia Health Cancer Center in Duluth, MN
- ★ Queen's Medical Center in Honolulu, HI
- ★ Sanford Medical Center and subcomponents
- ★ St. Joseph Mercy Hospital in Ann Arbor, MI
- ★ University of New Mexico Cancer Center in Albuquerque, NM

Congratulation to the following sites for enrolling their first patient as of 3/7/17:

- ★ Baptist Memorial Hospital and Cancer Center in Memphis, TN
- ★ LSU Health Sciences- Shreveport in Shreveport, LA
- ★ Spartanburg Medical Center in Spartanburg, SC
- ★ Oncology Associates at Mercy Medical Center in Cedar Rapids, IA

Thank you all for your participation in TrACER!

HICOR

SWOG
Leading cancer research. Together.

NCI Community Oncology Research Program
A program of the National Cancer Institute of the National Institutes of Health

FAQS OF THE MONTH - March, 2017

1. **In the Appendix 18.1 for approved treatments, under Breast, which agents make up TC?**
   TC is docetaxel and cyclophosphamide.

2. **Does a new metastatic lesion of a previously diagnosed and treated cancer qualify as a new current diagnosis per Section 5.1a, such that the treatments the patient would receive for the new lesion could be considered as "initial treatment for their current diagnosis" (per Section 5.2a)?**
   This would be considered treatment for progression of an existing cancer. The patient would be potentially eligible for the study as long as the patient had not received systemic therapy in the 180 days just prior to registration and meets all other S1415CD eligibility criteria.

HELPFUL INFORMATION/REMINDERS

- **Best practices for entering patient completed forms into Rave**
  Section 15.2d: As a general reminder, review all completed questionnaires to be sure all of the questions have been answered and, when the patient is directed to mark only one response, that only one answer is marked. If the patient has marked more than one answer per question, ask which answer reflects how the patient is feeling. If the patient has skipped a question, tell the patient that a question was not answered and ask if the patient would like to answer the question. If the patient is unable to answer the question at the time of the visit, site staffs are encouraged to retain the questionnaire and contact the patient by phone to obtain outstanding information. If patient does not want to answer a particular question, the CRA will enter "Not answered by the patient" in Medidata RAVE®.
- If you have any sub-components that will be participating in the trial with you (share the same Electronic Health Record (EHR)), please be sure to send us their CTEP IDs. If we do not have their CTEP IDs, they will not be included in the list to access the study database.
- Sites must obtain local IRB for this study; CIRB is not available. Let the TrACER team know if you run into any problems with this process.

Intervention sites:

- **Do not begin accruing patients until the HICOR team has approved your system changes.**
- Once you have an implementation plan in place, please contact TrACER@fredhutch.org to receive the Implementation questionnaire. **The completed questionnaire must be reviewed by HICOR prior to making changes in your system.**
- Contact the TrACER team if you need any consultant assistance in your order change process. We currently have consultants on call for EPIC, Mosaiq, Aria, Intellidose and Cerner. We are happy to source consultants for other systems upon request.

New Intervention sites:

- Please contact TrACER@fredhutch.org to set up a kick off phone call with the HICOR study team to review the order change process at your site.

Contact Us

Site Requirements, including regimen questions: HICOR, **TrACER@fredhutch.org**; phone: 206-667-7624
Patient eligibility, study procedures, and data submission: SWOG Data Ops, email: **cancercontrolquestion@crab.org**; phone: 206-652-2267